Clinical Trial Update: Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers [Phase 2]

View source ↗

Summary

Phase II study evaluating florbetaben PET imaging to detect or exclude cerebral beta-amyloid in patients with probable Alzheimer's disease; results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• florbetaben (florbetaben)

Snippet

Sponsor: Life Molecular Imaging SA | Conditions: Alzheimer Disease, Amyloid Beta-Protein | Phase 2 | Status: COMPLETED | Results posted: 2014-07-16